...drug discovery and clinical research. Eyevensys planning ocular gene therapy trial with $30M B round Eyevensys S.A.S....
...this year its aiSLE DX biomarker assay for early prediction of lupus flares. BioCentury Staff Airway Therapeutics LLC Eyevensys S.A.S. Intra-Cellular...

...Interim CFO Jeffrey Whitnell resigned. The company is seeking a principal financial officer. Ophthalmic company Eyevensys S.A.S....

...an information technology security company acquired by Hitachi Systems Security Inc. (Irvine, Texas). Ophthalmic company Eyevensys S.A.S....
...search for a principal financial officer. Jennie Walters Aeterna Zentaris Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics...

...Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date announced: 2016-09-15 Note: Eyevensys raised an undisclosed amount...

...delivery than the ophthalmic therapies that have entered the market in the last 10 years. Eyevensys...
...is also developing an anti-VEGF gene therapy to compete with Lucentis and Eylea. However, while Eyevensys'...
...because its approach offers a "number of key advantages over the other alternative therapeutic strategies." Eyevensys'...

...€3 million ($3.9 million) and invested in 10 companies, including French gene therapy ophthalmic play Eyevensys S.A.S....